Clinical trials of new biologics in patients with inflammatory bowel disease (IBD), such as upadacitinib (Rinvoq), have shown promising results, with remission rates from 50%-80%. But what about the remaining patients who remain unresponsive to therapy or intolerant of it?
Detransitioners and their advocates made their case against doctors, medical societies
Despite numerous treatments for acute severe ulcerative colitis (ASUC) that effectively reduce both symptom severity and disease complications — including corticosteroids as the current standard…
It’s too late to stop the ‘Big Beautiful Bill’ but it’s not too late to continue the fight
Exact amount still to be determined, agency says
It’s the first COVID shot to be fully approved for the youngest children
Attorney General says those that ‘mutilated children’ will be held accountable
Chemoradiation plus immunotherapy a winner in Chinese study
Brain edema risk expected to be less with new donanemab dosing schedule
All infections reduced by two-thirds; cost of care $9,000 lower
Claims about danger are ‘deliberately misleading,’ expert says
